Gene Test May ID Younger Women at Risk for Melanoma
... Identification of this variation in a gene called mdm2
could lead to a screening test to identify women a... further studies, the increased risk caused by the mdm2
variation "is higher than a lot of the other clini...percent of female patients younger than 50 had the mdm2
genetic variation, compared with about 16 percent ...
NYU study finds new risk factor for melanoma in younger women
...rongly, resulting in far greater production of the mdm2
Women with higher estrogen levels an... would be expected to have higher estrogen-related mdm2
protein that could increase their melanoma risk, explains Dr. Polsky.
genetic variant appears in the gene's promoter, a ...
Stabilizing cancer-fighting p53 can also shield a metastasis-promoter
... job is to degrade p53 when it's no longer needed. mdm2
also degrades the mutated version of the p53 prote.... Mice with the double-mutant p53 that also had no mdm2
died sooner and developed more aggressive metastat...mal Mdm2, to 9 percent in mice lacking one copy of mdm2
to 17 percent in mice with no Mdm2. Metastasis - t...
Effect of mutant p53 stability on tumorigenesis and drug design
...nesis, and lends startling new insight into the potential pitfalls of using mdm2
inhibitors for cancer therapy.
"Our data are both exciting and sobering:... interaction will also disrupt the Mdm2/mutant-p53 interaction. Thus, these mdm2
inhibitors will succeed in stabilizing mutant p53, and fail in preventing t...
Researchers Design Promising Cancer Drug
... of cancer, according to the researchers.
In almost all types of human cancer, p53 is inactivated. About half the time, this is because the protein mdm2
binds to p53 and inhibits the tumor-suppressor function of p53. In other cases, p53 dysfunction is due to a missing or mutated gene.
U-M researchers ID promising new cancer drug
... Using a computer-assisted approach, U-M researchers designed a small molecule, called MI-219, that is highly effective in blocking the interaction of mdm2
and p53. MI-219 specifically kills tumor cells by harnessing the power of p53. In animal models of human cancer, MI-219 completely inhibited tumor gro...
AACR's Seventh Annual Landon Awards
... in preventing the development of cancer.
Furthering his study of p53, Levine discovered another piece of the puzzle with the identification of the mdm2
oncoprotein as a potent inhibitor of p53. The milestone discovery of the Mdm2-p53 interaction has become, in recent years, a target for drug developm...
Oncoproteins double-team and destroy vital tumor-suppressor
...ubiquitins to the phosphorylated tumor suppressor, mdm2
marks it for destruction by the ubiquitin-proteasome degradation pathway.
"Both ERK and mdm2
are well-known oncoproteins, but their collaborati...ast cancer tumors, the researchers found that high mdm2
expression and low FOXO3a expression are associate...
Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference
...ncer Center, (Monday, Dec. 10, 8 a.m.). -- Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as Major Determinant of Response to mdm2
Inhibitors in Chronic Lymphocytic Leukemia, Shaomeng Wang, Ph.D., University of Michigan, (Dec. 10, 7:45 a.m.). -- IgVH Mutational Status Doe...
Advances in drug screening: building a better haystack for the needles of tomorrow
Identification of inhibitors for mdm2
ubiquitin ligase activity from natural products by... for a molecule that inhibits the known ability of mdm2
to signal for the destruction of the pro-apoptosis (cell suicide) protein p53. In normal cells, mdm2
and p53 exist in a state of benign equilibrium ba...
Study of placenta unexpectedly leads to cancer gene
...rectly regulates p53 activity through another protein called Mdm2, which was already known to be involved in some cancers. In cells lacking SENP2, the mdm2
becomes trapped in the nucleus, and is unable to halt p53, allowing it to accumulate within the cell. This disruption leads to distinct problems in ce...
Finnish scientists discovered a new approach to treat virus-induced lymphomas
...during PEL tumorigenesis. The results of this study demonstrate binding of the KSHV latency associated antigen LANA to both p53 and MDM2, and that the mdm2
inhibitor Nutlin-3a disrupts the p53-MDM2-LANA complex and selectively induces massive apoptosis in PEL cells. The cytotoxic effect of Nutlin-3a was s...
St. Jude announces breakthrough in eye cancer treatment
...s in mouse models. The molecule was originally developed by
Roche Pharmaceuticals (Nutley, N.J.) for a similar use against a related target called mdm2
in adult cancer cells. The success in knocking out MDMX with nutlin-3 represents the first example of local delivery of a targeted chemotherapy drug f...
Study pinpoints protein's role in cancer spread
...of the body's cells, the biochemical ratio between mdm2
and p53 can become unbalanced causing mdm2
to act as a cancer-promoting agent.
The proje...her at the University, explains: "One way in which mdm2
controls the p53 protein is by activating its dest...
p53, tumor suppression and aging
... to activate p53 in order to curb tumor formation. mdm2
is a key inhibitor of p53 and therefore an attract...erated aging.
To analyze the effects of reduced mdm2
levels on tumorigenesis ?as well as the potential ...team used mdm2-hypomorphic mice (that express less mdm2
protein than normal mice) which have elevated leve...
Loosen leash on cancer protein 'watchdog,' researchers say
...ease p53's activity without completely cutting its mdm2
The scientists spent three years creati... produced about 20 percent of the normal amount of mdm2
protein, which is far less than they would have pr...cer toolkit.
"Essentially, this study validates mdm2
as a potentially powerful chemopreventative for so...